Renal and Hepatic Dose Adjustment

Steady-state exposure is dose divided by clearance, so anything that halves clearance doubles the area under the curve at an unchanged regimen. Dose adjustment restores exposure either by lowering the amount given or by lengthening the interval, and which lever is used depends on whether the effect tracks peak concentration or total exposure. The numbers in a label come from dedicated pharmacokinetic studies in cohorts graded by organ function, not from theory.

Renal cutoffs are usually written as creatinine clearance bands estimated by the Cockcroft-Gault equation; clinics report an eGFR from a different equation, and substituting one for the other at the extremes of body size is a routine slip. Hepatic impairment is graded by Child-Pugh class. Peptides behave unlike small molecules here, because most are broken down to amino acids by peptidases distributed throughout the body, so several long-acting incretin analogues carry no renal adjustment even in severe impairment, whereas exenatide, which depends on glomerular filtration, is not recommended once renal function falls far enough.

The clinically useful point is that an absent adjustment is a positive finding rather than an omission. It means the study was done and exposure did not shift materially. It also does not remove the need for monitoring, since vomiting and dehydration during titration of a gut-slowing drug can precipitate acute kidney injury in someone whose baseline function was fine.

The error to avoid is generalising the mechanism. Peptides are not exempt from organ impairment simply because peptidases are ubiquitous; renal handling still dominates for small or filtered peptides, and impaired organs change protein binding, fluid balance and concomitant drug handling.